nodes	percent_of_prediction	percent_of_DWPC	metapath
Nitroglycerin—Abdominal colic—Vincristine—lymphatic system cancer	0.0599	0.0599	CcSEcCtD
Nitroglycerin—Hypotensive—Teniposide—lymphatic system cancer	0.0414	0.0414	CcSEcCtD
Nitroglycerin—Ischaemia—Mitoxantrone—lymphatic system cancer	0.0216	0.0216	CcSEcCtD
Nitroglycerin—Cyanosis—Teniposide—lymphatic system cancer	0.0213	0.0213	CcSEcCtD
Nitroglycerin—Hypoxia—Fludarabine—lymphatic system cancer	0.0209	0.0209	CcSEcCtD
Nitroglycerin—Intracranial pressure increased—Carmustine—lymphatic system cancer	0.0203	0.0203	CcSEcCtD
Nitroglycerin—Hypoxemia—Methotrexate—lymphatic system cancer	0.0196	0.0196	CcSEcCtD
Nitroglycerin—Pallor—Teniposide—lymphatic system cancer	0.0182	0.0182	CcSEcCtD
Nitroglycerin—Burning sensation—Carmustine—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Nitroglycerin—Coma—Fludarabine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Nitroglycerin—Paralysis—Vincristine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Nitroglycerin—Visual disturbance—Fludarabine—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Nitroglycerin—Stomatitis—Teniposide—lymphatic system cancer	0.00823	0.00823	CcSEcCtD
Nitroglycerin—Angina pectoris—Fludarabine—lymphatic system cancer	0.0081	0.0081	CcSEcCtD
Nitroglycerin—Sweating increased—Fludarabine—lymphatic system cancer	0.0081	0.0081	CcSEcCtD
Nitroglycerin—Sweating—Teniposide—lymphatic system cancer	0.00809	0.00809	CcSEcCtD
Nitroglycerin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00804	0.00804	CcSEcCtD
Nitroglycerin—Coma—Carmustine—lymphatic system cancer	0.00776	0.00776	CcSEcCtD
Nitroglycerin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Nitroglycerin—Coma—Vincristine—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0073	0.0073	CcSEcCtD
Nitroglycerin—Infection—Mechlorethamine—lymphatic system cancer	0.00725	0.00725	CcSEcCtD
Nitroglycerin—Stomatitis—Fludarabine—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Nitroglycerin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00709	0.00709	CcSEcCtD
Nitroglycerin—Flushing—Teniposide—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Nitroglycerin—Arrhythmia—Teniposide—lymphatic system cancer	0.00677	0.00677	CcSEcCtD
Nitroglycerin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Nitroglycerin—Visual impairment—Fludarabine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Nitroglycerin—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.0062	0.0062	CcSEcCtD
Nitroglycerin—Hypoxia—Methotrexate—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Nitroglycerin—Agitation—Teniposide—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Nitroglycerin—Arrhythmia—Fludarabine—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Nitroglycerin—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Nitroglycerin—Paralysis—Methotrexate—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Nitroglycerin—Burning sensation—Methotrexate—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Nitroglycerin—Cyanosis—Methotrexate—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Nitroglycerin—Confusional state—Teniposide—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Nitroglycerin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Nitroglycerin—Infection—Teniposide—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Nitroglycerin—Agitation—Fludarabine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Nitroglycerin—Stomatitis—Bleomycin—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Nitroglycerin—Tachycardia—Teniposide—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Nitroglycerin—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Nitroglycerin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Nitroglycerin—Hypotension—Teniposide—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Nitroglycerin—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Nitroglycerin—Dyspnoea—Teniposide—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Nitroglycerin—Confusional state—Fludarabine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Nitroglycerin—Infection—Fludarabine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Nitroglycerin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nitroglycerin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nitroglycerin—Stomatitis—Carmustine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Nitroglycerin—Rash—Mechlorethamine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Nitroglycerin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Nitroglycerin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Nitroglycerin—Flushing—Bleomycin—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Nitroglycerin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Nitroglycerin—Stomatitis—Vincristine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Nitroglycerin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Nitroglycerin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Nitroglycerin—Sweating—Vincristine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Nitroglycerin—Nausea—Mechlorethamine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Nitroglycerin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Nitroglycerin—Urticaria—Teniposide—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Nitroglycerin—Abdominal pain—Teniposide—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Nitroglycerin—Body temperature increased—Teniposide—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Nitroglycerin—Erythema—Bleomycin—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Nitroglycerin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Nitroglycerin—Sweating—Mitoxantrone—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Nitroglycerin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Nitroglycerin—Oedema peripheral—Carmustine—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Nitroglycerin—Visual impairment—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Nitroglycerin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Nitroglycerin—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Nitroglycerin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Nitroglycerin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Nitroglycerin—Flushing—Carmustine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Nitroglycerin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Nitroglycerin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Nitroglycerin—Asthenia—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Nitroglycerin—Pruritus—Teniposide—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Nitroglycerin—Arrhythmia—Carmustine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Nitroglycerin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Nitroglycerin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Nitroglycerin—Mental disorder—Carmustine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Nitroglycerin—Erythema—Carmustine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Nitroglycerin—Angiopathy—Vincristine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Nitroglycerin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Nitroglycerin—Coma—Methotrexate—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Nitroglycerin—Mental disorder—Vincristine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Nitroglycerin—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Nitroglycerin—Confusional state—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Nitroglycerin—Vision blurred—Carmustine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Nitroglycerin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Nitroglycerin—Erythema—Mitoxantrone—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Nitroglycerin—Infection—Bleomycin—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Nitroglycerin—Vomiting—Teniposide—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Nitroglycerin—Agitation—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Nitroglycerin—Asthenia—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nitroglycerin—Rash—Teniposide—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nitroglycerin—Dermatitis—Teniposide—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nitroglycerin—Headache—Teniposide—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Nitroglycerin—Pruritus—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Nitroglycerin—Agitation—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Nitroglycerin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Nitroglycerin—Hypotension—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Nitroglycerin—Nausea—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Nitroglycerin—Vertigo—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Nitroglycerin—Paraesthesia—Bleomycin—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Nitroglycerin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Nitroglycerin—Renal failure acute—Methotrexate—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Nitroglycerin—Confusional state—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Nitroglycerin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Nitroglycerin—Visual disturbance—Methotrexate—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Nitroglycerin—Infection—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Nitroglycerin—Vomiting—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Nitroglycerin—Rash—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Nitroglycerin—Dermatitis—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Nitroglycerin—Headache—Fludarabine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Nitroglycerin—Tachycardia—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Nitroglycerin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Nitroglycerin—Infection—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Nitroglycerin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Nitroglycerin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Nitroglycerin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Nitroglycerin—Hypotension—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Nitroglycerin—Nausea—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Nitroglycerin—Infection—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Nitroglycerin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Nitroglycerin—Shock—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Nitroglycerin—Urticaria—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Nitroglycerin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Nitroglycerin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Nitroglycerin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Nitroglycerin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Nitroglycerin—Paraesthesia—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Nitroglycerin—Hypotension—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Nitroglycerin—Dyspnoea—Carmustine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Nitroglycerin—Somnolence—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Nitroglycerin—Hypotension—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Nitroglycerin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nitroglycerin—Paraesthesia—Vincristine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Nitroglycerin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Nitroglycerin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Nitroglycerin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Nitroglycerin—Somnolence—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Nitroglycerin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Nitroglycerin—Feeling abnormal—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Nitroglycerin—Asthenia—Bleomycin—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Nitroglycerin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Nitroglycerin—Pruritus—Bleomycin—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Nitroglycerin—Body temperature increased—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Nitroglycerin—Abdominal pain—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Nitroglycerin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Nitroglycerin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Nitroglycerin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Nitroglycerin—Abdominal pain—Vincristine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Nitroglycerin—Body temperature increased—Vincristine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Nitroglycerin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Nitroglycerin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Nitroglycerin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Nitroglycerin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Nitroglycerin—Vomiting—Bleomycin—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Nitroglycerin—Drowsiness—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Nitroglycerin—Infestation NOS—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Nitroglycerin—Infestation—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Nitroglycerin—Rash—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Nitroglycerin—Dermatitis—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Nitroglycerin—Asthenia—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Nitroglycerin—Stomatitis—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Nitroglycerin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Nitroglycerin—Sweating—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Nitroglycerin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Nitroglycerin—Asthenia—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Nitroglycerin—Nausea—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Nitroglycerin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Nitroglycerin—Dizziness—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Nitroglycerin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Nitroglycerin—Vomiting—Carmustine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Nitroglycerin—Dizziness—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Nitroglycerin—Rash—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Nitroglycerin—Dermatitis—Carmustine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Nitroglycerin—Visual impairment—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Nitroglycerin—Headache—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Nitroglycerin—Vomiting—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Nitroglycerin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Nitroglycerin—Rash—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Nitroglycerin—Dermatitis—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Nitroglycerin—Headache—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Nitroglycerin—Nausea—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Nitroglycerin—Angiopathy—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Nitroglycerin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Nitroglycerin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Nitroglycerin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Nitroglycerin—Rash—Mitoxantrone—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Nitroglycerin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Nitroglycerin—Headache—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Nitroglycerin—Mental disorder—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Nitroglycerin—Erythema—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Nitroglycerin—Nausea—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Nitroglycerin—Nausea—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Nitroglycerin—Vision blurred—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Nitroglycerin—Vertigo—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Nitroglycerin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Nitroglycerin—Confusional state—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Nitroglycerin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Nitroglycerin—Infection—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Nitroglycerin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Nitroglycerin—Skin disorder—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Nitroglycerin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Nitroglycerin—Hypotension—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Nitroglycerin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Nitroglycerin—Dyspnoea—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Nitroglycerin—Somnolence—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Nitroglycerin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Nitroglycerin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Nitroglycerin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Nitroglycerin—Urticaria—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nitroglycerin—Body temperature increased—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nitroglycerin—Abdominal pain—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Nitroglycerin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Nitroglycerin—Asthenia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Nitroglycerin—Pruritus—Methotrexate—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Nitroglycerin—Dizziness—Methotrexate—lymphatic system cancer	0.000928	0.000928	CcSEcCtD
Nitroglycerin—Vomiting—Methotrexate—lymphatic system cancer	0.000892	0.000892	CcSEcCtD
Nitroglycerin—Rash—Methotrexate—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Nitroglycerin—Dermatitis—Methotrexate—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Nitroglycerin—Headache—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Nitroglycerin—Nausea—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
